|
1
|
Velazquez OC, Lederer HM and Rombeau JL:
Butyrate and the colonocyte. Dietary Fiber in Health and Disease.
Plenum Press; N.Y: pp. 123–134. 1977
|
|
2
|
Bourriaud C, Robins RJ, Martin L,
Kozlowski F, Tenailleau E, Cherbut C and Michel C: Lactate is
mainly fermented to butyrate by human intestinal microflora but
inter-individual variation is evident. J Appl Microbiol.
99:201–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mortensen PB and Clausen MR: Short-chain
fatty acids in the human colon: relation to gastrointestinal health
and disease. Scand J Gastroenterol Suppl. 216:132–148. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sengupta S, Tang CL, Wong CS, Tjandra JJ
and Gibson PR: Colonic epithelial atrophy induced by a fibre-free
diet in rats is reversed by minimal amounts of luminal butyrate,
but only in the short term. ANZ J Surg. 72:871–876. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Orchel A, Molin I, Dzierzewicz Z, Latocha
M, Weglarz L and Wilczok T: Quantification of p21 gene expression
in Caco-2 cells treated with sodium butyrate using real-time
reverse transcription-PCR (RT-PCR) assay. Acta Pol Pharm.
60:103–105. 2003.PubMed/NCBI
|
|
6
|
Ruemmele FM, Scwatrz S, Seidman EG, Dionne
S, Levy E and Lentze MJ: Butyrate induced Caco-2 cell apoptosis is
mediated via the mitochondrial pathway. Gut. 52:94–100. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rouet-Benzineb P, Aparicio T, Guilmeau S,
Pouzet C, Descatoire V, Buyse M and Bado A: Leptin counteracts
sodium butyrate-induced apoptosis in human colon cancer HT-29 cells
via NF-kappaB signaling. J Biol Chem. 279:16495–16502. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Augenlicht LH, Mariadason JM, Wilson A,
Arango D, Yang WC, Heerdt BG and Velcich A: Short chain fatty acids
and colon cancer. J Nutr. 132:3804S–3808S. 2002.PubMed/NCBI
|
|
9
|
Wachtershauser A and Stein J: Rationale
for the luminal provision of butyrate in intestinal diseases. Eur J
Nutr. 39:164–171. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Caderni G, Luceri C, Lancioni L, Tessitore
L and Dolara P: Slow-release pellets of sodium butyrate increase
apoptosis in the colon of rats treated with azoxymethane, without
affecting aberrant crypt foci and colonic proliferation. Nutrition
and Cancer. 30:175–181. 1998. View Article : Google Scholar
|
|
11
|
Hernandez A, Thomas R, Smith F, Sandberg
J, Kimschung DH and Evers BM: Butyrate sensitizes human colon
cancer cells to TRAIL-mediated apoptosis. Surgery. 130:265–272.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim YH, Park JW, Lee JY and Kwon TK:
Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of
transcription from DR5 gene promoter through Sp1 sites in colon
cancer cells. Carcinogenesis. 25:1813–1820. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Avivi-Green C, Polak-Charcon S, Madar Z
and Schwartz B: Different molecular events account for
butyrate-induced apoptosis in two human colon cancer cell lines. J
Nutr. 132:1812–1818. 2002.PubMed/NCBI
|
|
14
|
Menzel T, Schauber J, Kretch F, Kudlich T,
Mclcher R, Gostner A, Scheppach W and Luhrs H: Butyrate and aspirin
in combination have an enhanced effect on apoptosis in human
colorectal cancer cells. Eur J Cancer Prev. 11:271–281. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Avivi-Green C, Polak-Charcon S, Madar Z
and Schwartz B: Apoptosis cascade proteins are regulated in vivo by
high intracolonic butyrate concentration: correlation with colon
cancer inhibition. Oncol Res. 12:83–95. 2000.PubMed/NCBI
|
|
16
|
Haza AI, Glinghammar B, Grandien A and
Rafter J: Effect of colonic luminal components on induction of
apoptosis in human colonic cell lines. Nutr Cancer. 36:79–89. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Litvak DA, Hwang KO, Evers BM and Townsend
CM Jr: Induction of apoptosis in human gastric cancer by sodium
butyrate. Anticancer Res. 20:779–784. 2000.PubMed/NCBI
|
|
18
|
Berni Canani R, Di Costanzo M and Leone L:
The epigenetic effects of butyrate: potential therapeutic
implications for clinical practice. Clinical Epigenetics. 4:1–7.
2012.PubMed/NCBI
|
|
19
|
Kobayashi H, Tan EM and Fleming SE: Sodium
butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein
in human colonic adenocarcinoma cells independently of p53 status.
Nutr Cancer. 46:202–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Orchel A, Molin I, Dzierzewicz Z, Latocha
M, Weglarz L and Wilczok T: Quantification of p21 gene expression
in Caco-2 cells treated with sodium butyrate using real-time
reverse transcription-PCR (RT-PCR) assay. Acta Pol Pharm.
60:103–105. 2003.PubMed/NCBI
|
|
21
|
Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH
and Qui DK: Histone acetylation regulates p21 WAF1 expression in
human colon cancer cell lines. World J Gastroenterol. 10:2643–2646.
2004.PubMed/NCBI
|
|
22
|
Johnstone RW: Histone-deacetylase
inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug
Discov. 1:287–299. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Monneret C: Histone deacetylase
inhibitors. Eur J Med Chem. 40:1–13. 2005. View Article : Google Scholar
|
|
24
|
Joseph J, Wajapeyee N and Somasundaram K:
Role of p53 status in chemosensitivity determination of cancer
cells against histone deacetylase inhibitor sodium butyrate. Int J
Cancer. 115:11–18. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davie JR: Inhibition of histone
deacetylase activity by butyrate. J Nutr. 133(7 Suppl):
2485S–2493S. 2003.PubMed/NCBI
|
|
26
|
Nguyen KA, Cao Y, Chen JR, Townsend CM and
Ko TC: Dietary fiber enhances a tumor suppressor signalling pathway
in the gut. Ann Surg. 243:619–627. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu J, Cheng Y, Jönsson BA, Nilsson A and
Duan RD: Acid sphingomyelinase expression is stimulated by butyrate
but not functionally involved in cell proliferation and apoptosis
in HT29 and HepG2 cells. J Lipid Res. 46:1944–1952. 2005.
View Article : Google Scholar
|
|
28
|
Ahn EH and Schroeder JJ: Sphingoids bases
and ceramide induce apoptosis in HT-29 and HCT-116 human colon
cancer cells. Exp Biol Med (Maywood). 227:345–353. 2002.PubMed/NCBI
|
|
29
|
Parodi PW: Conjugated linoleic acid and
other anticarcinogenic agents of bovine milk fat. J Dairy Sci.
82:1339–1349. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berra B, Colombo I, Sottocornola E and
Giacosa A: Dietary sphingolipids in colorectal cancer prevention.
Eur J Cancer Prev. 11:193–197. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Celasco G, Moro L, Bozzella R, Mangano K,
Quattrocchi C, Aiello C, Donia M, Fagone P and Di Marco R: Efficacy
of intracolonic administration of low-molecular-weight heparin
CB-01-05, compared to other low-molecular-weight heparins and
unfractionated heparin, in experimentally induced colitis in rat.
Dig Dis Sci. 53:3170–3175. 2008. View Article : Google Scholar
|
|
32
|
Wargovich MJ, Harris C, Chen CD, Palmer C,
Steel VE and Kelloff GJ: Growth kinetics and chemoprevention of
aberrant crypts in the rat colon. J Cell Biochem Suppl. 16G:51–54.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vernia P, Annese V, Bresci G, d’Albasio G,
d’Incà R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D
and Caprilli R: Topical butyrate improves efficacy of 5-ASA in
refractory distal ulcerative colitis: results of a multicentre
trial. Eur J Clin Invest. 33:244–248. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vernia P: Butyrate in the treatment of
ulcerative colitis. Dig Liv Dis Suppl. 1:27–30. 2007.
|
|
35
|
Assisi RF; GISDI Study Group. Combined
butyric acid/mesalazine treatment in ulcerative colitis with
mild-moderate activity. Results of a multicentre pilot study.
Minerva Gastroenterol Dietol. 54:231–238. 2008.PubMed/NCBI
|
|
36
|
Di Sabatino A, Morera R, Ciccocioppo R,
Cazzola P, Gotti S, Tinozzi FP, Tinozzi S and Corazza GR: Oral
butyrate for mildly to moderately active Crohn’s disease. Aliment
Pharmacol Ther. 22:789–794. 2005.PubMed/NCBI
|
|
37
|
Scarpellini E, Lauritano EC, Lupascu A,
Petruzzellis C, Novi ML, Roccarina D, Gabrielli M, Serricchio M,
Gasbarrini G and Gasbarrini A: Efficacy of butyrate in the
treatment of diarrhoea-predominant irritable bowel syndrome. Dig
Liv Dis Suppl. 1:19–22. 2007.
|
|
38
|
Pereira MA, Barnes LH, Rassman VL, Kelloff
GV and Steele VE: Use of azoxymethane-induced foci of aberrant
crypts in rat colon to identify potential cancer chemopreventive
agents. Carcinogenesis. 15:1049–1054. 1994. View Article : Google Scholar
|
|
39
|
Velazquez OC, Lederer HM and Rombeau JL:
Butyrate and the colonocyte. Implications for neoplasia. Dig Dis
Sci. 41:727–739. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sengupta S, Muir GJ and Gibson PR: Does
butyrate protect from colorectal cancer? J Gastroenterol Hepatol.
21:209–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sigh NP and Lai HC: Synergistic
cytotoxicity of artemisin and sodium butyrate on human cancer
cells. Anticancer Res. 25:4325–4331. 2005.PubMed/NCBI
|
